Here’s something I can’t stop thinking about: there’s a lizard in the Sonoran Desert — the Gila monster — that eats maybe three or four times a year. It gorges, then basically shuts down for months. And buried in its venom is a peptide called exendin-4 that just so happens to mirror a hormone the human gut releases every time we eat. The difference? Our version, GLP-1, lasts maybe a minute or two in the bloodstream before an enzyme called DPP-4 chews it up. The Gila monster’s version is built to endure. Chemists looked at that structural resilience and thought: what if we could copy it?
That, in a crude nutshell, is the origin story behind the most talked-about drugs in modern medicine — semaglutide, tirzepatide, and their descendants — and it’s the beating heart of Enough: Your Health, Your Weight, And What It’s Like To Be Free, co-authored by Yale physician-scientist Dr. Ania M. Jastreboff and Oprah Winfrey. The book wants to accomplish something ambitious. It’s trying to convince you, at the level of both intellect and gut emotion, that obesity is not a character defect. It is a chronic, neurometabolic endocrine disease, full stop, and the new generation of GLP-1 and GIP receptor agonists aren’t vanity shortcuts — they’re serious pharmacology aimed at a biological system that has gone haywire in the modern world.
That’s a hell of a claim. And the trouble is, I think they mostly pull it off.
The Thermostat That Won’t Listen to You
The concept that anchors everything in Enough is what Jastreboff calls the “Enough Point” — clinically, the defended fat mass, or body fat set point. The metaphor she reaches for is a thermostat. Your brain, operating through subconscious hormonal feedback loops, has decided on a certain level of fat storage that it considers adequate. Fat tissue, the book insists, is not some inert warehouse. It’s an active endocrine organ pumping out hormones like leptin, signaling the brain about energy reserves in real time. And when the modern environment — ultra-processed food, chronic stress, wrecked sleep cycles, the whole catastrophe — corrupts those signals, the brain recalibrates the set point upward. It genuinely believes the body is starving, even when it isn’t.
So when someone diets, when they claw their way down to a lower weight through sheer restriction, the brain reads that deficit as a crisis. It deploys what Jastreboff calls “metabolic adaptation”: energy expenditure drops, hunger hormones like ghrelin spike, and the whole organism fights, tooth and nail, to drag itself back up to the defended set point. She compares this to holding your breath. You can white-knuckle it for a while. But survival biology will, eventually, force you to gasp.
What’s striking about this framing isn’t just the science, which is solid. It’s the emotional weight it carries. This is the section of the book that functions almost as an absolution. If your body is battling you at a systems level — if metabolic adaptation is a documented, measurable phenomenon — then decades of cultural messaging about discipline and moral fortitude start to look not just unhelpful but actively cruel.
The evidence base here is the Rockefeller University study, led by Drs. Rudy Leibel, Michael Rosenbaum, and Jules Hirsch. They controlled participants’ diets precisely enough to force either a 10% gain or a 10% loss in body weight. Those who lost weight became metabolically more efficient — they burned fewer calories at rest. Those who gained weight started burning more. The body was fighting in both directions to return to baseline, completely indifferent to what the conscious mind wanted. I’ll grant them this: if you wanted one study to demolish the “calories in, calories out” dogma, this is a pretty devastating choice.
Jastreboff writes something that stayed with me: “It’s just as easy to lose weight as it ever was to gain weight… Finally, her brain felt that her body had enough. She felt a sense of ease. In fact, the origin of the word ‘disease’ is ‘lack of ease.’ So treating the disease brought her ease.” The etymology is a bit cute, maybe. But the underlying logic is genuinely persuasive.
The Noise Inside Your Head
There’s a companion concept that Winfrey, more than Jastreboff, brings to life: “food noise.” The idea is that when someone lives chronically below their biological set point — which is essentially what every dieter with obesity is doing — the brain generates intrusive, relentless thoughts about food. Not casual “what’s for dinner” musings. Something closer to obsessive ideation. The homeostatic and hedonic centers, governing hunger and reward, simply overpower the prefrontal cortex, the part of the brain responsible for deliberate choice.
Winfrey’s own testimony on this front is probably the most emotionally raw section of the book. She describes the sheer cognitive load: “All that energy I spent on ‘What am I gonna eat? What am I not gonna eat? What am I gonna eat next? What did I just eat? What shouldn’t I have eaten?’ has somehow been channeled into a desire to experience life differently… Now that I’ve released it, I am free.” There’s something almost uncomfortably confessional about it, coming from someone who’s spent decades being scrutinized in public for her weight. But that transparency is doing real rhetorical work. It makes the science personal.
The book also points to the Food Noise Questionnaire, or FNQ, developed at the Pennington Biomedical Research Center in 2024 — a clinical instrument designed to actually measure this phenomenon, asking patients to rate statements like “My thoughts about food distract me from what I need to do.” That a formal clinical tool now exists to quantify what millions of people have felt privately but couldn’t articulate, and that it was developed this recently, tells you something about how slow medicine has been to take this seriously.
From Poison to Gila Spit: A Pharmacological History
This is where things get weird — and, honestly, where I found the book most compelling, because the history of obesity treatment reads like a catalog of desperation. The authors frame it as a cautionary tale born from medicine’s failure to understand obesity as a brain disease. Early interventions went after metabolism directly: DNP, a toxic industrial compound that French munitions workers in the 1930s were observed losing weight from, got repurposed as a diet aid. Thyroid hormone extracts. Amphetamines, sold as “rainbow pills.” These were blunt instruments. They lacked any targeted mechanism and the off-target effects were, in many cases, lethal.
The breakthrough, when it finally arrived, came from an unexpected direction. Nutrient-Stimulated Hormones — NuSHs, in Jastreboff’s terminology — specifically GLP-1 and GIP, are incretin hormones naturally released by the gut when food is consumed. They signal satiety to the brain and prompt insulin release from the pancreas. But native human GLP-1 survives barely a minute or two in the bloodstream, degraded almost instantly by the DPP-4 enzyme. Useless as a drug.
Enter the Gila monster. A desert reptile that eats a handful of times per year. Its venom contains exendin-4 — a peptide structurally similar to human GLP-1 but resistant to DPP-4 degradation. By reverse-engineering that durability, chemists built drugs that persist in the body for an entire week, constantly whispering to the brain’s satiety centers. As the book puts it: “These peptides became the new NuSH-based medications. And just as the chemists predicted, they have half-lives of not just minutes but days… they communicate, ‘Hey! Reduce the fuel you’re storing. You’ll be just fine. You won’t starve. You’ll survive! You’re okay!'”
The narrative arc from poisonous industrial chemicals to lizard spit to precision pharmacology spanning the 1930s through the isolation of incretins in the 1970s to the modern dual-receptor agonists — it’s a genuinely good piece of science storytelling. Jastreboff knows how to trace a thread. And the progression matters because it contextualizes why earlier drugs failed: they were fighting the wrong war, targeting symptoms while the neurometabolic machinery hummed along unperturbed.
The Numbers That Changed Everything
The clinical trial data is where Jastreboff gets to flex her credentials — she was a lead investigator on several of these studies — and the numbers really are staggering by historical standards. Previous obesity pharmacology yielded a modest 5 to 10 percent reduction in body weight. Semaglutide, tested in the STEP 1 trial in 2021, delivered an average reduction of over 15 percent. But it was the SURMOUNT-1 trial in 2022, lead-authored by Jastreboff herself, that genuinely shocked people: tirzepatide, a dual GIP/GLP-1 receptor agonist, produced an average weight reduction of nearly 23 percent — over 50 pounds. “The data spoke for itself: Patients lost on average more than 22% of their body weight… Their blood pressure improved. Their cholesterol improved. Their blood sugars improved. Their health improved.”
The mechanism is two-pronged. These drugs slow gastric emptying, creating a sense of physical fullness, while simultaneously recalibrating the brain’s satiety and reward centers. The body fat set point itself gets lowered. But the authors are careful — and I appreciate this — to note that obesity is a heterogeneous disease. Not everyone responds the same way. Some patients are “super responders”; others need combination therapies. The aim, they repeatedly insist, is not cosmetic weight loss but measurable reduction in adiposity and the prevention of the 200-plus comorbidities that trail behind obesity like a shadow.
Fair enough. Though I noticed how smoothly the distinction between “cosmetic” and “medical” weight loss does a lot of ideological heavy lifting throughout the text. More on that in a moment.
The Long Game: Chronic Disease, Chronic Treatment
The section on the realities of ongoing treatment is important and, I think, slightly undercooked. The authors are clear that stopping NuSH medications causes the original, elevated Enough Point to reassert itself. Weight comes back. Obesity is chronic; treatment is chronic. They compare it, reasonably, to statins for cholesterol or antihypertensives for blood pressure. Nobody asks why a patient with hypertension can’t just “try harder” to lower their blood pressure without pills.
But rapid weight loss on these drugs also carries real risks — loss of lean muscle mass, decreased bone density, gallstone formation (illustrated through a patient named Quisha). The recommended protocol is “Start Low, Go Slow,” keeping the dose at the lowest effective level while weight trends downward, paired with resistance training, optimized protein intake, and rigorous sleep hygiene. The SELECT cardiovascular outcomes trial gets cited here to prove these drugs aren’t just shrinking waistlines: semaglutide was shown to reduce the risk of secondary heart attacks and strokes in non-diabetic patients with obesity. That’s significant. That moves the conversation from weight management into cardiology.
“Weight loss does not mean a cure,” the book states flatly. “For this to be a ‘cure,’ the Enough Point would have to remain at its lower setting in the absence of the medication… Normal blood sugars in the face of active treatment do not mean the diabetes has been cured — rather it is referred to as well-controlled diabetes.” That kind of honesty about the limitations of pharmacological intervention earns my respect. It’s the right framing.
The Blind Spot: When the Cure Is a Subscription
I’ll be honest—I almost put the book down here. Or rather, I almost stopped reading the summary, which I suppose is the more accurate and less dramatic way to say it. The science is compelling. The exoneration of individuals trapped in a rigged biological system is genuinely moving. But the proposed solution is, overwhelmingly, pharmaceutical. And the summary acknowledges this without quite grappling with it.
The authors identify the obesogenic environment—ultra-processed food, chronic stress, systemic inequality, busted circadian rhythms—as the thing that breaks the thermostat in the first place. And then their answer is: here’s a very expensive drug you’ll need to take forever. The summary notes that Jastreboff mentions the lack of Medicare coverage and the dangers of unregulated compounding pharmacies, but frames these as logistical problems to be solved rather than symptoms of a deeper structural crisis. What about the food system that’s doing the breaking? What about the fact that the populations most harmed by the obesogenic environment are the same populations least likely to afford a weekly injection that costs over a thousand dollars without insurance?
The trouble is, the book—at least as this summary renders it—treats lifelong pharmaceutical dependency as something close to an unalloyed victory. And maybe, for the individual patient suffering right now, it is. I don’t want to minimize that. But there is a version of this story where the pharmaceutical industry becomes the permanent landlord of a problem that was substantially created by the food industry, and the systemic reforms that might actually lower the thermostat for everyone just never arrive because there’s too much money in selling the fix. The summary mentions upcoming triple-receptor agonists like retatrutide. We are talking about artificially manipulating multiple hormonal axes for decades. The long-term, multi-decade effects of that intervention are, to use the summary’s own cautious phrasing, “biologically uncharted territory.” That should probably bother us more than it seems to bother the authors.
This doesn’t invalidate the science. It complicates the narrative. And I would have liked the book to sit with that complication longer.
Where the Book Stands: Biological Realism and Its Neighbors
The summary situates the book alongside several works I found interesting to consider. Peter Attia’s Outlive shares the thesis that aggressive targeting of metabolic dysfunction is key to preserving healthspan. Gary Taubes’ Good Calories, Bad Calories and Chris van Tulleken’s Ultra-Processed People overlap in diagnosing the problem—metabolic syndrome, food industry capture—but diverge sharply on solutions. Taubes and van Tulleken want systemic dietary overhaul. Jastreboff and Winfrey pragmatically argue that once the biological set point is broken, pharmacology is the most reliable lever to fix it. Matthew Walker’s Why We Sleep connects as well, given the book’s emphasis on sleep as a metabolic regulator. It’s a useful constellation. The book seems to be positioning itself at the pharmacological end of a spectrum of biological realism in health writing, and that’s a legitimate intellectual address even if I wish it had more to say about the neighborhood.
The Winfrey Factor
The Action Plan (Or: The Part I Almost Skipped)
I’ll be honest — I almost put the book down in the practical application section. It’s fine. It’s competent. It reads like a well-organized patient handout. Separate self-worth from body weight. Audit metabolic markers beyond BMI — HbA1c, lipid panels, waist-to-height ratio. Use the “Start Low, Go Slow” protocol with your prescriber. Pivot from cardio-heavy exercise to heavy resistance training to preserve muscle. Accept that a weight plateau isn’t failure, it’s your new recalibrated set point. Track trigger foods in a journal. Get DEXA scans to monitor body composition. Set hydration timers because NuSH medications blunt thirst cues alongside hunger.
All perfectly sensible. None of it surprised me. The trouble is it sits at the back of the book like an appendix when, for many readers, it’s probably the part they’ll actually use. But it doesn’t belong in a long essay about ideas, so I’ll leave it there.
The Medicalization Problem (Or: What the Book Won’t Say Out Loud)
Here’s where I push back, and I’ll push back hard. Enough does a brilliant job reframing obesity as biology rather than morality. The science communication is excellent — the thermostat analogy for the hypothalamus’s regulation of the body fat set point is one of the clearest pedagogical tools I’ve encountered in popular health writing, and Winfrey’s presence is not a gimmick; her decades-long, very public struggle with diet culture provides an emotional gravity that Jastreboff’s clinical prose alone couldn’t achieve.
But the book has a massive blind spot, and it’s one the authors clearly see but deliberately walk past.
They acknowledge the “obesogenic environment.” They name it. Ultra-processed food. Chronic stress. Systemic inequality. Disrupted circadian rhythms. All of it. And then — having identified the environmental conditions that miscalibrate the Enough Point in the first place — they spend the rest of the book proposing a solution that is almost entirely pharmacological. There’s a brief, careful mention of the socioeconomic barriers: the lack of Medicare coverage, the dangers of unregulated compounding pharmacies churning out knockoff semaglutide. But these get treated as logistical speed bumps on the road to pharmaceutical salvation rather than as symptoms of a deeper systemic failure.
What about the food systems? What about the political economy that floods the market with engineered hyperpalatable products specifically designed to override satiety signals? The book barely touches this. And the omission matters, because the implicit argument becomes: the environment broke your biology, and now you must take a drug — possibly for the rest of your life — to compensate. That’s a real thing to ask of someone. Especially someone without insurance, or without $1,000 a month for a branded injectable.
There’s also a whiff of utopianism around the future pipeline. Triple-receptor agonists like retatrutide are mentioned. So is CagriSema. But the long-term, multi-decade consequences of artificially manipulating several hormonal axes simultaneously? That territory is genuinely uncharted. The authors mention this briefly. They don’t dwell. And I think they should.
I don’t doubt the science. The STEP and SURMOUNT and SELECT data are real. The biology of the set point is real. The suffering of people trapped in the food-noise cycle is real. But a book that identifies an environmental catastrophe and then prescribes an individual pharmaceutical remedy — without seriously grappling with the structural reforms that might prevent the problem upstream — ends up telling a story that is, at some level, incomplete. It shifts blame from the patient, yes. But it quietly shifts responsibility from society to the pharmacy, and I’m not sure those are the same thing.
Where It Sits on the Shelf
The book fits naturally alongside Peter Attia’s Outlive, sharing its thesis that aggressively targeting metabolic dysfunction is the key to healthspan. It also speaks — sometimes in direct contradiction — to Gary Taubes’ Good Calories, Bad Calories and Chris van Tulleken’s Ultra-Processed People. Those writers advocate systemic dietary overhaul. Jastreboff and Winfrey essentially say: once the set point is broken, pharmacology is the most reliable lever to fix it. Both positions can be true simultaneously, of course, but Enough clearly picks its lane and sticks to it. The emphasis on sleep as a metabolic regulator echoes Matthew Walker’s Why We Sleep, which reinforces the authors’ point about the interconnectedness of biology. Everything links to everything. Except, apparently, food policy.
A Lizard in the Desert
I keep coming back to the Gila monster. There’s something almost literary about it — this sluggish, venomous creature that eats almost never, carrying in its spit the molecular key to quieting the modern human brain’s relentless, misguided hunger. The image works. Maybe too well. Because the Gila monster doesn’t live in our environment. It doesn’t eat our food. It solved its own energy problem millions of years ago and then just… stopped.
We haven’t stopped. We built a world of engineered overconsumption and now we’re borrowing a lizard’s chemistry to cope with it. Jastreboff and Winfrey have written a smart, compassionate, scientifically serious book about that coping. What they haven’t written — what maybe nobody yet has — is the book about why we needed the lizard’s help in the first place, and whether we always will.
If you’d like to read the full book in EPUB or MOBI format, feel free to send me an email—I’d be happy to share a free copy with you. Please reach me at: thenovaleaf@gmail.com